Abstract
Crizotinib is the first clinically available tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and is associated with the development of complex renal cysts. We now describe a 39-year-old woman who developed infected complex renal cysts during crizotinib treatment. After 10 months of such treatment, she presented with a high fever and low back pain. Computed tomography findings were consistent with complex renal cysts and perilesional inflammation. Interventions including cyst drainage and antibiotic administration contributed to diagnosis and management of the infected cysts.
| Original language | English |
|---|---|
| Pages (from-to) | 510-512 |
| Number of pages | 3 |
| Journal | Investigational New Drugs |
| Volume | 33 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 1 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Pharmacology
- Pharmacology (medical)
Cite this
Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement. / Yoneshima, Yasuto; Okamoto, Isamu; Arimura-Omori, Masako; Kimura, Shinichi; Hidaka-Fujimoto, Noriko; Iwama, Eiji; Harada, Taishi; Takayama, Koichi; Nakanishi, Yoichi.
In: Investigational New Drugs, Vol. 33, No. 2, 01.04.2015, p. 510-512.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement
AU - Yoneshima, Yasuto
AU - Okamoto, Isamu
AU - Arimura-Omori, Masako
AU - Kimura, Shinichi
AU - Hidaka-Fujimoto, Noriko
AU - Iwama, Eiji
AU - Harada, Taishi
AU - Takayama, Koichi
AU - Nakanishi, Yoichi
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Crizotinib is the first clinically available tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and is associated with the development of complex renal cysts. We now describe a 39-year-old woman who developed infected complex renal cysts during crizotinib treatment. After 10 months of such treatment, she presented with a high fever and low back pain. Computed tomography findings were consistent with complex renal cysts and perilesional inflammation. Interventions including cyst drainage and antibiotic administration contributed to diagnosis and management of the infected cysts.
AB - Crizotinib is the first clinically available tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and is associated with the development of complex renal cysts. We now describe a 39-year-old woman who developed infected complex renal cysts during crizotinib treatment. After 10 months of such treatment, she presented with a high fever and low back pain. Computed tomography findings were consistent with complex renal cysts and perilesional inflammation. Interventions including cyst drainage and antibiotic administration contributed to diagnosis and management of the infected cysts.
UR - http://www.scopus.com/inward/record.url?scp=84939796705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939796705&partnerID=8YFLogxK
U2 - 10.1007/s10637-014-0195-1
DO - 10.1007/s10637-014-0195-1
M3 - Article
C2 - 25433426
AN - SCOPUS:84939796705
VL - 33
SP - 510
EP - 512
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 2
ER -